Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer
* Must have responded and remained clinically stable (as defined by normal clinical examination, normal serum CA125 level and normal CT scan) after first-line platinum-based regimen followed by bevacizumab maintenance therapy
* Must have developed relapsed disease at least 3 months after completion of bevacizumab maintenance therapy as defined by a) development of new, measurable lesions by RECIST criteria, but no lesion with maximum diameter greater than 3 centimeters OR b) newly elevated CA125 level at least 2 x ULN on 2 separate occasions, obtained at least 1 day but not more than 3 months apart
* ECOG Performance Status 0-2
* No prior cytotoxic chemotherapy or biologic therapy for disease recurrence allowed
* Prior hormonal-based therapy for ovarian, primary peritoneal serous or fallopian tube cancer is allowed
* Toxic side effects related to prior chemotherapy or hormonal therapy must have resolved to grade one or less or to baseline before initiation of bevacizumab
* 18 years of age or older
* Life expectancy of 6 months or greater
* Normal organ and marrow function as outlined in the protocol

Exclusion Criteria:

* Prior cytotoxic chemotherapy or biologic therapy for disease recurrence
* Known CNS disease, except for treated brain metastasis
* Pregnancy or breast feeding
* Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study
* Core biopsy or other minor surgical procedure, excluding placement of a vascular device, within 7 days prior to enrollment
* History of abdominal fistula, GI perforation, intra-abdominal abscess, or CT evidence of bowel obstruction or bowel wall thickening
* Symptoms of intestinal obstruction, or requirement of parenteral hydration and/or nutrition
* History of active malignancy during the last 3 years, except non-melanomatous skin cancer or in situ breast or cervical cancer
* Evidence of preexisting uncontrolled hypertension. If patient has hypertension, it must be medically controlled (\< 150/90) prior to starting bevacizumab
* Proteinuria at screening
* Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent
* Therapeutic anticoagulation is not by itself and exclusion criterion. However, for certain high risk patients on therapeutic anticoagulation, eligibility will be determined after discussion with the overall PI
* Any active bleeding
* Serious, non-healing wound, ulcer, or bone fracture
* Prior history of hypertensive crisis or hypertensive encephalopathy
* NYHA Grade II or greater congestive heart failure
* History of myocardial infarction or unstable angina within 6 months prior to Day 1
* History of stroke or transient ischemic attack within 6 months prior to day 1
* Significant vascular disease within 6 months prior to day 1
* History of hemoptysis within 1 month prior to day 1
* Presence of measurable lesion(s) by RECIST criteria with maximum diameter greater than 3 centimeters